GlobeNewswire: Allarity Therapeutics, Inc. Contains the last 10 of 474 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T08:55:26ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853146/0/en/Allarity-Therapeutics-Makes-Strategic-Pivot-to-Focus-Solely-on-Accelerating-Stenoparib-Toward-Regulatory-Approval-in-Advanced-Recurrent-Ovarian-Cancer.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer2024-03-27T12:30:00Z<![CDATA[]]>https://www.globenewswire.com/news-release/2024/03/25/2851509/0/en/Allarity-Therapeutics-Receives-Extension-from-Nasdaq-Hearings-Panel-to-Regain-Compliance-with-Listing-Rules-5550-a-2-and-5550-b-1.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)2024-03-25T11:30:00Z<![CDATA[Boston (March 25, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company has been granted a formal extension until April 24, 2024 to regain compliance under Nasdaq Listing Rules 5550(a)(2) (the “Bid Price Rule”) and 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements in Listing Rule 5550(b).]]>https://www.globenewswire.com/news-release/2024/03/08/2843041/0/en/Allarity-Therapeutics-Reports-Full-Year-2023-Financial-Results-and-Provides-a-Business-Update.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update2024-03-08T12:15:00Z<![CDATA[Boston (March 8, 2024) — Allarity Therapeutics, Inc. (“Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended December 31, 2023, and provided a general business update.]]>https://www.globenewswire.com/news-release/2024/02/28/2836723/0/en/Allarity-Therapeutics-to-Present-at-Biomarkers-2024.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics to Present at Biomarkers 20242024-02-28T11:00:00Z<![CDATA[Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.]]>https://www.globenewswire.com/news-release/2023/12/12/2794551/0/en/Allarity-Therapeutics-Announces-Thomas-Jensen-as-Interim-CEO-and-Appointment-of-Jeremy-R-Graff-PhD-as-Key-Executive-Advisor.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor2023-12-12T11:00:00Z<![CDATA[Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced a transition in its leadership. Effective immediately, James G. Cullem is no longer President and CEO. The Company also announced that Thomas H. Jensen, co-founder and member of the Board of Directors of Allarity Therapeutics, has been appointed as Interim Chief Executive Officer. The Company has also engaged Jeremy R. Graff, Ph.D., as an Executive Advisor. Dr. Graff will work closely with Mr. Jensen and the Board to provide consulting and advisory services on Allarity’s research and development programs in the field of small molecule inhibitors and their use in the treatment of cancer.]]>https://www.globenewswire.com/news-release/2023/12/05/2790791/0/en/Allarity-s-Early-Phase-2-Stenoparib-Data-Indicates-Clinical-Benefit-in-Women-with-Advanced-Ovarian-Cancer-Selected-with-DRP-Companion-Diagnostic.html?f=22&fvtc=4&fvtv=30186Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic2023-12-05T12:30:00Z<![CDATA[Boston (December 5, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable disease.]]>https://www.globenewswire.com/news-release/2023/10/02/2752599/0/en/Allarity-Therapeutics-to-Present-at-Biomarkers-Europe-2023.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics to Present at Biomarkers Europe 20232023-10-02T11:00:00Z<![CDATA[BOSTON, October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity’s development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx.]]>https://www.globenewswire.com/news-release/2023/08/30/2734776/0/en/PLOS-ONE-Publishes-Data-on-Allarity-Therapeutics-DRP-Companion-Diagnostic-for-Dovitinib.html?f=22&fvtc=4&fvtv=30186PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib2023-08-30T20:05:00Z<![CDATA[- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients]]>https://www.globenewswire.com/news-release/2023/07/31/2714654/0/en/Allarity-Therapeutics-and-FivepHusion-Announce-Collaboration-to-Support-Clinical-Development-of-Deflexifol-with-DRP-Companion-Diagnostics.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics2023-07-31T10:00:00Z<![CDATA[BOSTON and SYDNEY (July 31, 2023) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, and Detsamma Investments Pty. Ltd. trading as “FivepHusion,” an advanced clinical-stage biotechnology company developing Deflexifol™, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV), announced today that the two companies have entered into a Clinical Collaboration Agreement. Under this agreement, Allarity will support FivepHusion’s future clinical development of Deflexifol™ for the treatment of solid tumors by using certain of Allarity’s drug-specific DRP® companion diagnostics, including its validated DRP®-5FU companion diagnostic, to potentially select patients for enrollment and treatment in clinical trials of Deflexifol™ as a monotherapy and in combination with other drugs.]]>https://www.globenewswire.com/news-release/2023/07/24/2709344/0/en/Allarity-Therapeutics-Strengthens-Board-of-Directors-with-Appointment-of-Three-Accomplished-Biotechnology-Executives.html?f=22&fvtc=4&fvtv=30186Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives2023-07-24T10:00:00Z<![CDATA[]]>